MarketPulse

alopecia areata

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Nektar Therapeutics Faces Class Action Over Failed Trial and Alleged Disclosure Failures

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.
NKTRclass action lawsuitstock decline
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Investigation After Failed Trial Announcement

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.
NKTRshareholder lawsuitstock price decline